The logo of Celltrion is seen at company's headquarters in Incheon, South Korea, October 28, 2016. Picture taken on October 28, 2016. REUTERS/Kim Hong-Ji

SEOUL (Reuters) -South Korean pharmaceutical company Celltrion said on Wednesday that it plans to invest up to 700 billion Korean won ($478.17 million) to expand capacity at its U.S. factory in response to U.S. tariffs and rising demand.

($1 = 1,463.9000 won)

(Reporting by Hyunjoo JinEditing by Ed Davies)